Skip to main content
logo
Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
39.94
-1.76 (-4.22%)
Aug 20, 2026, 4:00 PM EDT - Market closed

Celldex Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.161.557.026.882.364.65
Revenue Growth
-97.27%-77.99%1.99%192.02%-49.32%-37.30%
Gross Profit
-278.65-243.53-156.53-111.13-79.9-48.66
Operating Income
-325.83-287.37-195.08-142.04-107.1-69.15
Net Income
-300.55-258.76-157.86-141.43-112.33-70.51
Earnings Per Share
-4.33-3.90-2.45-2.92-2.40-1.64
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
717.59518.57725.28423.6304.95408.25
Total Debt
4.92.343.812.544.033.04
Net Cash (Debt)
712.68516.24721.47421.06300.92405.21
Net Cash Growth
13.61%-28.45%71.35%39.92%-25.74%112.22%
Net Cash Per Share
10.287.7711.208.696.429.45

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-235.57-210.95-157.78-107.29-103.73-60.91
Capital Expenditures
-6.54-2.71-1.92-1.82-1.83-1.25
Free Cash Flow
-242.11-213.66-159.7-109.11-105.56-62.16
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
-206220.25%-18599.81%-2778.89%-2063.66%-4543.74%-1486.73%
Pretax Margin
-190220.89%-16748.03%-2248.76%-2054.76%-4765.59%-1520.92%
Profit Margin
-190220.89%-16748.03%-2248.76%-2054.76%-4765.59%-1516.04%
FCF Margin
-153231.01%-13829.06%-2274.89%-1585.19%-4478.57%-1336.44%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
19851.071168.13238.82315.12890.64387.68